# Safety and Efficacy Study With Catumaxomab in Patients After Curative Resection of a Gastric Adenocarcinoma

> **NCT00352833** · PHASE2 · COMPLETED · sponsor: **Neovii Biotech** · enrollment: 40 (estimated)

## Conditions studied

- Gastric Cancer
- Gastric Adenocarcinoma

## Interventions

- **DRUG:** catumaxomab

## Key facts

- **NCT ID:** NCT00352833
- **Lead sponsor:** Neovii Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07
- **Primary completion:** —
- **Final completion:** 2007-09
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2007-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00352833

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00352833, "Safety and Efficacy Study With Catumaxomab in Patients After Curative Resection of a Gastric Adenocarcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00352833. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*